Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Initiates Coverage On BioNTech with In-Line Rating, Announces Price Target of $100

Author: Benzinga Newsdesk | May 14, 2024 05:10am
Evercore ISI Group analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ:BNTX) with a In-Line rating and announces Price Target of $100.

Posted In: BNTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist